It happens when clinical and commercial work hand in hand together. When the walls between disciplines come down and are replaced by the sharing of data and critical insights. When everyone in the company begins their work with the ultimate end in mind. Biopharmaceutical acceleration is a game changer and it’s happening here.
Average study start-up time four weeks faster than industry average. 1
Database lock faster than industry average. 1
Helped to develop or commercialize at least 82% of all Novel New Drugs approved by the FDA in a recent five year period.
At least 70% of products granted marketing authorization by the EMA in a recent five-year period.
1Based on reported benchmarks from CMR International Institute for Regulatory Science
For more information or questions related to the merger, please contact the individuals below:
Investor Relations Contact:
Vice President, Investor Relations
+1 919 745 2745
Senior Director, External Communications
+1 202 210 5992